Document is current
Any future updates will be listed below
-
Authors
Catrina, Sergiu-Bogdan https://orcid.org/0000-0002-6914-3902
Amadid, Hanan https://orcid.org/0000-0001-5759-4960
Braae, Uffe C. https://orcid.org/0000-0002-2743-4584
Dereke, Jonatan https://orcid.org/0000-0002-5653-8614
Ekberg, Neda Rajamand https://orcid.org/0000-0001-5597-2593
Klanger, Boris https://orcid.org/0009-0003-3507-9724
Jansson, Stefan https://orcid.org/0000-0001-6864-4679
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04601753 at ClinicalTrials.govDocuments that mention this clinical trial
PIONEER REAL Sweden: A Multicentre, Prospective, Real-World Observational Study of Oral Semaglutide Use in Adults with Type 2 Diabetes in Swedish Clinical Practice
https://doi.org/10.1007/s13300-024-01614-6
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies
https://doi.org/10.1007/s13300-024-01668-6
-
Funding
Funding for this research was provided by:
Novo Nordisk A/S
- License Information
-
More Information
Article History
Received: 3 April 2024
Accepted: 19 June 2024
First Online: 25 July 2024
Declarations
:
: Sergiu-Bogdan Catrina and Neda Rajamand Ekberg have nothing to disclose. Hanan Amadid, Uffe C. Braae and Jonatan Dereke are employees of and shareholders in Novo Nordisk. Boris Klanger has received grants for co-operation with the following companies during the last 5 years: Novo Nordisk, Boehringer Ingelheim, Bayer, AstraZeneca, Pfizer, Lilly, Abbott, Sanofi, Amgen, Amarin, Teva, Region Västmanland and Novartis. Stefan Jansson’s employer has received all his speaking fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Novo Nordisk.
: The study was conducted in line with Good Pharmacoepidemiology Practices [] and Good Pharmacovigilance Practices [], and physicians had to comply with applicable regulatory requirements and the requirements in the Declaration of Helsinki. Study-specific documentation was submitted to the relevant national body, and the study was approved by the independent ethics committee or institutional review board for each participating centre. The independent ethics committee for each site was Etikprövningsmyndigheten, Uppsala, Sweden. Participants provided written informed consent prior to commencement of any study-related activity.
